Viability.

What's new, wild, and true in biotech.

Before finance, there was biology. I studied biomedical science and molecular biology, then forensic biology and toxicology — the sciences of how life works and how it ends. Then I spent years as a COO, then a CFO, ending up at a NASDAQ-listed company, learning how companies work and how they end.

Now I read biotech papers and press releases for fun, pull at threads, and dig into what's new, wild, and true at Viability. Each piece takes a new company, piece of tech, or idea and works out what's real and what's mostly marketing. I write for biotech investors and founders, and for anyone who wants to know what's underneath the headline.